Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-blind, Placebo-controlled Study, in COPD Patients With and Without a Confirmed Respiratory Virus Infection Assessing Anti-viral Biomarker Responses and Clinical Effects of Inhaled SNG001 Compared to Placebo

Trial Profile

A Randomised, Double-blind, Placebo-controlled Study, in COPD Patients With and Without a Confirmed Respiratory Virus Infection Assessing Anti-viral Biomarker Responses and Clinical Effects of Inhaled SNG001 Compared to Placebo

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors Synairgen
  • Most Recent Events

    • 30 Sep 2019 According to a Synairgen media release, trial is expected to complete dosing in Q1 2020, with results available in Q2 2020.
    • 30 Sep 2019 According to a Synairgen media release, trial is progressing well with four new sites added in year 2019. At 30 June 2019, 43 confirmed virus-positive patients had been dosed. At 27 September 2019, this had increased to 55 patients.
    • 27 Sep 2019 According to a Synairgen media release, biomarker data from the first part of this study is presenting at the European Respiratory Society (ERS) International Congress being held in Madrid 28 September -2 October 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top